We also previously reported that direct AMPK activation (via PXL770 treatment) has anti-inflammatory effects: including reducing total liver leukocytes - monocytes and resident macrophages – and suppressing MCP-1 levels in a diet-induced obese NASH mouse model, as well as inhibiting proinflammatory cytokine production in human macrophages (Gluais-Dagorn et al., 2022). Here, PRKAA1 is linked to metabolic dysfunction-associated steatohepatitis.